| Literature DB >> 30208955 |
Valérie Biancalana1,2,3,4,5, Norma B Romero6,7,8, Inger Johanne Thuestad9, Jaakko Ignatius10, Janne Kataja11, Maria Gardberg12, Delphine Héron13, Edoardo Malfatti7,8, Anders Oldfors14, Jocelyn Laporte15,16,17,18.
Abstract
Entities:
Keywords: Centronuclear myopathy; Congenital myopathy; DNM2; Hypotonia; MTM1
Mesh:
Substances:
Year: 2018 PMID: 30208955 PMCID: PMC6134552 DOI: 10.1186/s40478-018-0593-2
Source DB: PubMed Journal: Acta Neuropathol Commun ISSN: 2051-5960 Impact factor: 7.801
Fig. 1a. Hematoxilin-eosin (HE) and nicotinamide adenosine dinucleotide-tetrazolium reductase (NADH-TR) staining of muscles from the patients, showing fibers with centralized nuclei (HE) and abnormal central accumulation oxidative staining and a paler peripheral halo. Scale bars 20 μm. b. Electron microscopy of patient 1 muscle showing partial sarcomeres disorganisation and central nuclei. Scale bar 10 μm. c. Localization of presently reported mutations (dark blue) compared to known DNM2-CNM mutations (red) on the 3D model of nucleotide-free human DNM1 (PDB 3SNH). They all clusterize at the PH (yellow) – Middle/stalk (light blue) interface (green line)